• disease
  • This result was not dependent on bilirubin levels above the reference range, liver disease, or alcohol intake. (ahajournals.org)
  • Probiotics have been proposed as a treatment option for patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis because of their balancing role on the flora of the gut that may act as a potential source of hepatotoxic oxidative injury. (cochrane.org)
  • This review did not identify any randomised clinical trials with probiotics in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. (cochrane.org)
  • Even if the results from pilot studies seem promising, randomised clinical trials are necessary to asses the clinical implication of probiotics therapy in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. (cochrane.org)
  • The lack of randomised clinical trials makes it impossible to support or refute probiotics for patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. (cochrane.org)
  • Non-alcoholic fatty liver disease comprises a spectrum of diseases ranging from simple steatosis to non-alcoholic steatohepatitis, fibrosis, and cirrhosis. (cochrane.org)
  • To evaluate the beneficial and harmful effects of probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. (cochrane.org)
  • Randomised clinical trials evaluating probiotic treatment in any dose, duration, and route of administration versus no intervention , placebo , or other interventions in patients with non-alcoholic fatty liver disease. (cochrane.org)
  • Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. (cochrane.org)